PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly
differentiated, multi-product, commercial-stage medical technology
company, and its digital health subsidiary Veris Health (“Veris”)
today announced the appointment of Silicon Valley technology
executive Sunny Webb as Veris’ Chief Technology Officer and
PAVmed’s VP, Data & Analytics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211025005453/en/
Sunny Webb appointed as Chief Technology
Officer for PAVmed Digital Health Subsidiary Veris Health (Photo:
Business Wire)
Ms. Webb will be joining other Veris leaders and guest panelists
for the PAVmed digital health virtual investor event, Veris Heath:
Bringing Digital Health to Cancer Care, to be held tomorrow,
October 26, 2021, from 1:00 P.M. to 3:00 P.M. EDT. Attendees may
register for the event here.
“I am very pleased to welcome Sunny Webb to the PAVmed and Veris
team,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief
Executive Officer and Veris’ Executive Chairman. “Ms. Webb is a
Silicon Valley veteran and Stanford Graduate School of Business
alum who brings nearly two decades of experience successfully
leading technology teams and launching dozens of enterprise-level
software and hardware products. In her technology career she has
collaborated with industry leaders such as Apple, Phillips
Healthcare and Facebook to solve some of their most complex
technology challenges. Ms. Webb has deep expertise in data science,
analytics, machine learning, and advanced sensors—technologies
central to the Veris device and platform. We are fortunate to have
such a highly accomplished technology executive join the Veris
program at this critical juncture, as the software development
process with Loka is moving full-steam ahead, and as we leverage
our important relationship with Microsoft.”
“I am thrilled to join this remarkable team and look forward to
utilizing my skills and experience to advance Veris’ mission to
create an integrated digital healthcare platform for millions of
cancer patients and their oncologists,” said Ms. Webb. “We have the
far-reaching opportunity to improve cancer care by offering
physiologic and clinical data-driven management tools and data
analytics - including machine learning, artificial intelligence,
and other cutting-edge technologies - to patients, health care
providers, payors, biotech companies, and other key
stakeholders.”
Ms. Webb most recently served as Co-Founder and Managing Partner
of Hummingbird Search Partners, a boutique private equity firm
focused on healthcare technology. Prior to that, she spent a decade
at leading global professional services firm Accenture and its
dedicated research and development arm, Accenture Labs. As
Accenture’s Apple global product lead, she established the product
strategy and vision and built the team and technology that enabled
clients in complex technology stacks. As Senior Principal,
Engineering and Product Lead at Accenture Labs, she led a team of
more than 75 engineers to build and launch over 50 new enterprise
products incorporating advanced sensors, machine learning,
analytics, robotics, VR and other evolving technologies. She also
oversaw $25 million to invest into innovation and product with
nearly a dozen major clients, including Philips Healthcare,
Facebook, Disney, The National Park Service, P&G and Shell,
among others. Earlier in her career at Accenture she served as a
data scientist, integrating data from hundreds of systems for
contracts with the U.S. Department of Defense. Ms. Webb also
previously served as Executive Director of The Accelerator at the
University of Southern Mississippi, a technology incubator with
contracts from Boeing, Rawlings and others, and founded SWD, a
company which built full-stack analytics and web solutions for
dozens of clients.
Ms. Webb is an inventor with more than thirty patents in machine
learning, analytics, three-dimensional rendering and other areas.
She earned her undergraduate degree in Management Information
Systems at Pennsylvania State University and her Masters from the
Stanford Graduate School of Business, where she completed the
Masters of Science in Management Program as a Sloan Fellow and
served as Class President and Academic Chair. Ms. Webb has also
served on the Computer Engineering Industry Board of California
Polytechnic State University and as an Executive Sponsor of Girls
Who Code.
Veris, a majority-owned subsidiary of PAVmed, acquired Oncodisc
Inc., a digital health company with groundbreaking tools to improve
personalized cancer care in May 2021. Veris is developing a remote
cancer care platform that integrates an intelligent implantable
vascular access port with physiologic sensing, software with
symptom reporting and telehealth functions, and advanced data
analytics. Veris’ groundbreaking vascular access port contains
biologic sensors capable of generating continuous data on key
physiologic parameters known to predict adverse outcomes in cancer
patients undergoing treatment. Wireless communication to the
patient’s smartphone and its cloud-based digital healthcare
platform seek to deliver actionable real-time data to patients and
physicians efficiently and effectively. Veris is targeting FDA
510(k) clearance of the intelligent implantable vascular access
port and launch of the remote digital healthcare platform for
H2-2022.
Recently, Veris entered into a relationship with Microsoft as
part of a global program which provides access to Microsoft
technology, mentorship and business support and allows it to
leverage Microsoft’s cloud storage, data analytics, and other
technologies to rapidly build and deploy its platform with
state-of-the-art, built-in redundancy and security. Veris’ Silicon
Valley-based full-stack software development partner Loka Inc. will
build the Veris platform on Microsoft Azure, which includes Azure
AI & Machine Learning clinical analytics, Azure IoT patient
monitoring, and numerous other cutting-edge healthcare focused
products and services.
About PAVmed and Veris
PAVmed Inc. is a highly differentiated, multi-product,
commercial-stage medical technology company with a diversified
product pipeline addressing unmet clinical needs encompassing a
broad spectrum of clinical areas with attractive regulatory
pathways and market opportunities. Its major subsidiary, Lucid
Diagnostics Inc. (Nasdaq: LUCD), markets the first and only
commercial tools for widespread early detection of esophageal
precancer and cancer – the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device. Its GI Health division
also includes the complementary EsoCure™ Esophageal Ablation Device
with Caldus™ Technology. Another major subsidiary, Veris Health
Inc., is a digital health company developing the first intelligent
implantable vascular access port with biologic sensors and wireless
communication to improve personalized cancer care through remote
patient monitoring. Its Minimally Invasive Interventions division
markets its CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome. Other divisions include Infusion Therapy (PortIO™
Implantable Intraosseous Vascular Access Device and NextFlo™
Intravenous Infusion Set), and Emerging Innovations (non-invasive
laser-based glucose monitoring, pediatric ear tubes, and mechanical
circulatory support). For more information, please visit
www.pavmed.com, follow us on Twitter, connect with us on LinkedIn,
and watch our videos on YouTube.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of
PAVmed’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, the ability to complete the initial
public offering of Lucid; volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211025005453/en/
Investors Lisa DeScenza
LaVoieHealthScience (617) 351-0243
ldescenza@lavoiehealthscience.com
Media Kristi Bruno
LaVoieHealthScience (617) 792-3937 / (617) 865-3940
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Feb 2024 to Mar 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Mar 2023 to Mar 2024